Bill Wexler's Profits of DOOM Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Bill Wexler's Profits of DOOM

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Bill Wexler who wrote (4579)	3/3/1999 9:31:00 AM
From: CMason	Read Replies (2) of 4634

HEPH has really plummeted over the last two days. In addition to the departure of their President (ex Drexel Burnham guy, LOL), and a shaky sounding release that they're starting Phase I/II trials for an unidentified AIDS/HIV compound, I wonder if this had anything to do with it: Trials show DHEA ineffective for Alzheimer's SAN DIEGO, March 2 (Reuters) - Drug company Neurocrine Biosciences (Nasdaq:NBIX - news) said Tuesday clinical trials of the dietary supplement DHEA showed it to be ineffective in treating Alzheimer's disease. The company had been studying the neurosteroid in a phase II/III trial since anecdotal evidence suggested it might be useful in treating the disease. You had speculated some months ago that DHEA was the basis of at least one of the company's investigational drugs. Regardless, the decline is certainly helping my position with this stock! Regards, CMason

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next